Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin
Completed · Phase 2
Conditions studied: Ovarian Cancer, Peritoneal Cavity Cancer
In brief
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving lapatinib together with topotecan may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving lapatinib together with topotecan works in treating patients with ovarian epithelial cancer or primary peritoneal cancer that did not respond to cisplatin or carboplatin.
Key facts
- Study ID
- NCT00436644
- Run by
- Mayo Clinic
- People needed
- 18
- Starts
- 2007-03-01
- Expected to finish
- 2012-11-01
- Last updated by the study team
- 2014-04-16
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic Arizona — Scottsdale, Arizona, United States
- Mayo Clinic in Jacksonville — Jacksonville, Florida, United States
- Mayo Clinic Cancer Center — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.